Europäische Union - Deutsch - EMA (European Medicines Agency)

amgen europe b.v. - panitumumab - kolorektale neoplasmen - antineoplastische mittel - vectibix is indicated for the treatment of adult patients with wild-type ras metastatic colorectal cancer (mcrc): , in first-line in combination with folfox or folfiri. in second-line in kombination mit folfiri bei patienten, die empfangen haben der first-line-fluoropyrimidine-basierten chemotherapie (ohne irinotecan). - als monotherapie nach versagen von fluoropyrimidine-, oxaliplatin-und irinotecan-haltigen chemotherapien.

Europäische Union - Deutsch - EMA (European Medicines Agency)

amgen europe bv - sotorasib - karzinom, nicht kleinzellige lunge - antineoplastische mittel - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.

Europäische Union - Deutsch - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - vorläuferzelle lymphoblastische leukämie-lymphom - antineoplastische mittel - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Europäische Union - Deutsch - EMA (European Medicines Agency)

amgen europe b.v. - carfilzomib - multiples myelom - antineoplastische mittel - kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

amgen europe - filgrastim r-met-hug-csf - injektionslösung - 0.3 mg/ml - filgrastim r-met-hug-csf - filgrastim

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

amgen europe - filgrastim r-met-hug-csf - injektionslösung in einer fertigspritze - 48 mio u (0,96 mg/ml) - filgrastim r-met-hug-csf - filgrastim

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

amgen europe - filgrastim r-met-hug-csf - injektionslösung in einer fertigspritze - 30 mio u (0,6 mg/ml) - filgrastim r-met-hug-csf - filgrastim

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

amgen switzerland ag - filgrastimum - injektionslösung - filgrastimum 30 mio. u., acidum aceticum glaciale, natrii hydroxidi solutio 18% m/m corresp. natrium 31.9 µg, polysorbatum 80, sorbitolum 50 mg, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - neutropenie - biotechnologika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

amgen switzerland ag - filgrastimum adnr - injektionslösung - filgrastimum adnr 48 mio. u., natrii acetas trihydricus, sorbitolum, polysorbatum 80, wasser iniectabilia q.s. zu einer lösung anstelle von 1,6 ml. - neutropenie - biotechnologika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

amgen switzerland ag - filgrastimum - injektionslösung in einer fertigspritze - filgrastimum 30 mio. u., acidum aceticum glaciale, natrii hydroxidi solutio 18% m/m corresp. natrium 15.9 µg, polysorbatum 80, sorbitolum 25 mg, aqua ad iniectabile q.s. ad solutionem pro 0.5 ml. - neutropenie - biotechnologika